Background Oral pre-exposure prophylaxis has been introduced in more than 70 countries,
including many in sub-Saharan Africa, but women experience considerable barriers to daily …

Background: HPTN 084 is a Phase 3 randomized, double-blind, double-dummy superiority
trial evaluating safety and efficacy of long-acting injectable cabotegravir (CAB) compared to …

Abstract Background HIV Prevention Trials Network 084 demonstrated that long-acting
injectable cabotegravir (CAB) was superior to daily oral tenofovir (TFV) disoproxil fumarate …

Background Safe and effective long-acting injectable agents for preexposure prophylaxis
(PrEP) for human immunodeficiency virus (HIV) infection are needed to increase the options …

Abstract Background The HIV Prevention Trials Network (HPTN) 083 trial demonstrated that
long-acting cabotegravir (CAB-LA) was more effective than tenofovir disoproxil fumarate …

Background Cabotegravir (GSK1265744) is an HIV-1 integrase strand transfer inhibitor with
potent antiviral activity and a long half-life when administered by injection that prevented …

In this guideline, WHO recommends that long-acting injectable cabotegravir (CAB-LA) may
be offered as an additional HIV prevention option for people at substantial risk of HIV …

Background Long-acting injectable cabotegravir is a novel integrase inhibitor currently in
advanced clinical development for HIV prevention and treatment. We aimed to assess the …

Background: Cabotegravir (GSK1265744) is an integrase strand transfer inhibitor in
development as a long-acting (LA) intramuscular injectable suspension for HIV-1 pre …

PrEP, after approval of Truvada, continues to evolve to address adherence limitations of
daily dosing. As a long-acting injectable antiretroviral drug, cabotegravir long-acting permits …